JP2010213710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010213710A5 JP2010213710A5 JP2010101148A JP2010101148A JP2010213710A5 JP 2010213710 A5 JP2010213710 A5 JP 2010213710A5 JP 2010101148 A JP2010101148 A JP 2010101148A JP 2010101148 A JP2010101148 A JP 2010101148A JP 2010213710 A5 JP2010213710 A5 JP 2010213710A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- administered
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 3
- 210000000214 mouth Anatomy 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 claims 1
- 241000309551 Arthraxon hispidus Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000860 cochlear nerve Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004373 mandible Anatomy 0.000 claims 1
- 210000002050 maxilla Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003681 parotid gland Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02116259.X | 2002-03-26 | ||
| CNB02116259XA CN1219882C (zh) | 2002-03-18 | 2002-03-26 | 以erbb－3为基础的用于肿瘤治疗的方法和组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Division JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010213710A JP2010213710A (ja) | 2010-09-30 |
| JP2010213710A5 true JP2010213710A5 (OSRAM) | 2011-06-16 |
| JP5249282B2 JP5249282B2 (ja) | 2013-07-31 |
Family
ID=28048642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Expired - Fee Related JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
| JP2010101148A Expired - Lifetime JP5249282B2 (ja) | 2002-03-26 | 2010-04-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Expired - Fee Related JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7919098B2 (OSRAM) |
| EP (2) | EP2400021B1 (OSRAM) |
| JP (2) | JP4660094B2 (OSRAM) |
| CN (1) | CN100424175C (OSRAM) |
| AU (1) | AU2003218600C1 (OSRAM) |
| CA (1) | CA2480099C (OSRAM) |
| WO (1) | WO2003080835A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| MX2008005640A (es) * | 2005-11-02 | 2008-12-09 | Univ Duke | Quimioterapia e inmunoterapia concurrentes. |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| BRPI0808055A2 (pt) * | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| WO2009157919A1 (en) * | 2008-06-23 | 2009-12-30 | Tumor Biology Investment Group, Inc. | SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER |
| AU2009281721A1 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| EP2808339B1 (en) | 2008-11-28 | 2017-02-15 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin peptides and their use |
| EP2370093A4 (en) * | 2008-11-28 | 2012-08-29 | Zensun Shanghai Science And Technology Ltd | NEUREGULIN AND CARDIAC STEM CELLS |
| LT2719708T (lt) | 2009-11-13 | 2018-02-12 | Daiichi Sankyo Europe Gmbh | Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui arba prevencijai |
| MX2012007340A (es) | 2009-12-22 | 2012-08-01 | Roche Glycart Ag | Anticuerpos anti/her3 y usos de los mismos. |
| PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| ITRM20100577A1 (it) * | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
| TWI418362B (zh) * | 2010-11-19 | 2013-12-11 | Univ Nat Pingtung Sci & Tech | 溶血性巴斯德桿菌重組外膜脂蛋白e及含此之疫苗組成物 |
| CN103562226A (zh) | 2011-03-11 | 2014-02-05 | 梅里麦克制药股份有限公司 | 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌 |
| CA2828043A1 (en) | 2011-03-15 | 2012-09-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP3608340A1 (en) | 2011-11-23 | 2020-02-12 | Medlmmune, LLC | Binding molecules specific for her3 and uses thereof |
| US9956276B2 (en) * | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016011343A1 (en) * | 2014-07-17 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Her3 peptides and dendritic cell vaccines |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| JP2018527286A (ja) * | 2015-07-17 | 2018-09-20 | ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． | 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定 |
| US11090284B2 (en) | 2015-09-02 | 2021-08-17 | The Cleveland Clinic Foundation | Ovarian cancer vaccines |
| WO2017120576A1 (en) | 2016-01-07 | 2017-07-13 | Duke University | Cancer vaccines and methods of delivery |
| CN110167968B (zh) * | 2016-09-15 | 2023-11-28 | 斯图加特大学 | 针对her3的抗原结合蛋白 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| US11890335B2 (en) * | 2017-09-27 | 2024-02-06 | L2 Diagnostics, Llc | ErbB peptide pharmaceutical and vaccine compositions and therapeutic uses thereof for cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| AU645760B2 (en) | 1989-08-04 | 1994-01-27 | Berlex Laboratories, Inc. | C-erbb-2 external domain: GP75 |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| AU1057097A (en) | 1995-12-22 | 1997-07-17 | Beth Israel Deaconess Medical Center | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| EP1728802A3 (en) | 1996-03-27 | 2006-12-13 | Genentech, Inc. | ErbB3 antibodies |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| EP0938556B1 (en) * | 1996-07-12 | 2005-03-09 | Genentech, Inc. | Gamma-heregulin |
| CN100415772C (zh) | 1996-10-18 | 2008-09-03 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
| WO1998035036A1 (en) | 1997-02-10 | 1998-08-13 | Genentech, Inc. | Heregulin variants |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| US5962274A (en) | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| CA2377665A1 (en) | 1999-07-06 | 2001-01-11 | General Atomics | Methods and compositions for assaying analytes |
| CZ20023748A3 (cs) | 2000-05-15 | 2003-04-16 | Pharmacia Italia S.P.A. | Inhibitory aromatasy a monoklonální anti-HER2 protilátky jako protitumorová činidla |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| RU2007135216A (ru) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | Биспецифические связывающие агенты для модулирования биологической активности |
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
-
2003
- 2003-03-26 AU AU2003218600A patent/AU2003218600C1/en not_active Ceased
- 2003-03-26 CN CNB038067625A patent/CN100424175C/zh not_active Expired - Fee Related
- 2003-03-26 WO PCT/CN2003/000217 patent/WO2003080835A1/en not_active Ceased
- 2003-03-26 EP EP11178809.7A patent/EP2400021B1/en not_active Expired - Lifetime
- 2003-03-26 CA CA2480099A patent/CA2480099C/en not_active Expired - Fee Related
- 2003-03-26 JP JP2003578561A patent/JP4660094B2/ja not_active Expired - Fee Related
- 2003-03-26 EP EP03711804.9A patent/EP1495123B1/en not_active Expired - Lifetime
- 2003-03-26 US US10/516,759 patent/US7919098B2/en not_active Expired - Lifetime
-
2010
- 2010-04-26 JP JP2010101148A patent/JP5249282B2/ja not_active Expired - Lifetime
-
2011
- 2011-02-25 US US13/035,244 patent/US20110229478A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010213710A5 (OSRAM) | ||
| AU2024264558B2 (en) | Bicyclic peptide ligands specific for Nectin-4 | |
| TWI868726B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| TWI712423B (zh) | 抗ｔｒｏｐ２抗體-藥物結合物之製造方法 | |
| ES2852973T3 (es) | Composiciones de receptores de antígeno quimérico | |
| ES2717911T3 (es) | Combinaciones farmacéuticas que comprenden un inhibidor de B-Raf, un inhibidor de EGFR y opcionalmente un inhibidor de PI3K-alfa | |
| JP2014526462A5 (OSRAM) | ||
| JP2011130770A5 (OSRAM) | ||
| JP2013513559A5 (OSRAM) | ||
| JP2012509259A5 (OSRAM) | ||
| JP2018522822A5 (OSRAM) | ||
| JP2010531140A5 (OSRAM) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2015534577A5 (OSRAM) | ||
| JP2018502120A5 (OSRAM) | ||
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| US10449227B2 (en) | Conjugates for immunotherapy | |
| AU2014318545A1 (en) | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof | |
| HRP20160506T1 (hr) | Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba | |
| JP2010529026A5 (OSRAM) | ||
| JP2014500862A5 (OSRAM) | ||
| ITRM20100577A1 (it) | Immunoterapia contro il recettore erbb-3 | |
| JP2015517523A5 (OSRAM) | ||
| WO2023061457A1 (zh) | 抗体药物偶联物及其用途 | |
| JP2008500277A5 (OSRAM) |